Anelia Horvath1, Constantine A Stratakis. 1. Section on Endocrinology and Genetics, Program on Developmental Endocrinology & Genetics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1862, USA.
Abstract
PURPOSE OF REVIEW: The present review discusses the molecular basis of micronodular adrenal hyperplasia. It focuses on the role of genetic defects in cyclic-AMP (cAMP) signaling-related molecules, namely PRKAR1A, GNAS, PDE11A, and PDE8B in the predisposition to tumor formation. This review also discusses the involvement of cAMP signaling and related pathways and their impact on the adrenocortical tumor formation. RECENT FINDINGS: Molecular abnormalities in the phosphodiesterases family are the most recently discovered genetic abnormalities that predispose individuals to various adrenocortical tumors. In contrast to GNAS and PRKAR1A, defects in phosphodiesterases are associated more frequently with incomplete penetrance. SUMMARY: Recent findings indicate the importance of cAMP signaling for normal adrenocortical functioning and the sensitivity of the adrenal gland to subtle alterations in cAMP levels. The identification of low-penetrance mutations in more than one phosphodiesterase in patients with adrenocortical hyperplasia is suggestive for a complementary role of the different phosphodiesterases in adrenal gland abnormalities and possible involvement of other members of this pathway in adrenocortical tumor defects.
PURPOSE OF REVIEW: The present review discusses the molecular basis of micronodular adrenal hyperplasia. It focuses on the role of genetic defects in cyclic-AMP (cAMP) signaling-related molecules, namely PRKAR1A, GNAS, PDE11A, and PDE8B in the predisposition to tumor formation. This review also discusses the involvement of cAMP signaling and related pathways and their impact on the adrenocortical tumor formation. RECENT FINDINGS: Molecular abnormalities in the phosphodiesterases family are the most recently discovered genetic abnormalities that predispose individuals to various adrenocortical tumors. In contrast to GNAS and PRKAR1A, defects in phosphodiesterases are associated more frequently with incomplete penetrance. SUMMARY: Recent findings indicate the importance of cAMP signaling for normal adrenocortical functioning and the sensitivity of the adrenal gland to subtle alterations in cAMP levels. The identification of low-penetrance mutations in more than one phosphodiesterase in patients with adrenocortical hyperplasia is suggestive for a complementary role of the different phosphodiesterases in adrenal gland abnormalities and possible involvement of other members of this pathway in adrenocortical tumor defects.
Authors: P V Gejman; L S Weinstein; M Martinez; A M Spiegel; Q Cao; W T Hsieh; M R Hoehe; E S Gershon Journal: Genomics Date: 1991-04 Impact factor: 5.736
Authors: Daniel F Gunther; Isabelle Bourdeau; Ludmila Matyakhina; David Cassarino; David E Kleiner; Kurt Griffin; Nickolas Courkoutsakis; Mones Abu-Asab; Maria Tsokos; Meg Keil; J Aidan Carney; Constantine A Stratakis Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: O Caticha; W D Odell; D E Wilson; L A Dowdell; R H Noth; A L Swislocki; J J Lamothe; R Barrow Journal: J Clin Endocrinol Metab Date: 1993-08 Impact factor: 5.958
Authors: Mark Veugelers; David Wilkes; Kimberly Burton; Deborah A McDermott; Yan Song; Marsha M Goldstein; Krista La Perle; Carl J Vaughan; Art O'Hagan; Kenneth R Bennett; Beat J Meyer; Eric Legius; Mervi Karttunen; Reijo Norio; Helena Kaariainen; Michael Lavyne; Jean-Philippe Neau; Gert Richter; Kaan Kirali; Alan Farnsworth; Karen Stapleton; Peter Morelli; Yoshinori Takanashi; John-Steven Bamforth; Franz Eitelberger; Irene Noszian; Waldimiro Manfroi; James Powers; Yoshihiko Mochizuki; Tsuneo Imai; Gary T C Ko; Deborah A Driscoll; Elizabeth Goldmuntz; Jay M Edelberg; Amanda Collins; Diana Eccles; Alan D Irvine; G Stanley McKnight; Craig T Basson Journal: Proc Natl Acad Sci U S A Date: 2004-09-15 Impact factor: 11.205
Authors: C Gicquel; M Leblond-Francillard; X Bertagna; A Louvel; Y Chapuis; J P Luton; F Girard; Y Le Bouc Journal: Clin Endocrinol (Oxf) Date: 1994-04 Impact factor: 3.478
Authors: F Beuschlein; M Reincke; M Karl; W D Travis; C Jaursch-Hancke; S Abdelhamid; G P Chrousos; B Allolio Journal: Cancer Res Date: 1994-09-15 Impact factor: 12.701